Cobra Biologics Announces Development Projects

Cobra Biologics and Novolytics announced that the companies have developed two Staphylococcus aureus-based phage products for Phase I clinical trials with a 100-fold increase in upstream process yields. An existing process was transferred to Cobra’s phage team, which further developed the process in order to increase yields for the two S. aureus-based phage products. The process provides a path to producing suitable GMP material for human clinical trials, according to a Cobra Biologics press release.

In May, Cobra and Recopharma, a biotechnology company developing ophthalmic products, announced that Cobra Biologics will use its maxXpress platform service to deliver a program of vector construction using the UCOE technology, transfectant pool generation, and supply, purification, and protein characterization for a human Fc-fusion protein.

Cobra also announced that it will manufacture Vaccibody’s lead DNA vaccine candidate against HPV-induced malignancies, using its platform process to deliver a program of host strain generation, GMP cell banking, plasmid DNA production, and clinical trials supply.